Business Context and Reporting Period
This Form 8-K reports on the 2016 Annual Meeting of Stockholders held by GlycoMimetics, Inc. on May 17, 2016. The filing details the results of two proposals submitted to security holders. Note: The request metadata references "Crescent Biopharma, Inc.," but the filing text explicitly identifies the registrant as "GlycoMimetics, Inc."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Of the 19,330,396 shares outstanding, 16,845,577 shares (87.1%) were present or represented by proxy. The results for the proposals were as follows:
- Proposal 1: Election of Directors
- John J. Baldwin, Ph.D.: Elected (13,642,749 For; 604,666 Withheld)
- M. James Barrett, Ph.D.: Elected (13,616,645 For; 630,770 Withheld)
- John L. Magnani, Ph.D.: Elected (13,668,949 For; 578,466 Withheld)
- Broker Non-Votes: 2,598,162
- Proposal 2: Ratification of Auditors
- Ernst & Young LLP was ratified as the independent registered public accounting firm.
- Votes: 16,834,072 For; 11,409 Against; 96 Abstained.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Investor Verification Checklist
- Verify the registrant name discrepancy between the request metadata (Crescent Biopharma) and the filing (GlycoMimetics).
- Confirm the tenure of the newly elected directors (until the 2019 annual meeting).
- Review the definitive proxy statement filed on April 11, 2016, for detailed background on the proposals.